Also from this source

You just read:

Aspyrian Therapeutics Inc. Closes $4.25M Series A Extension Financing to Support the Execution of Phase 1 Clinical Studies of the Precision Targeted Cancer Therapy, RM-1929, to Treat Late-Stage Recurrent Head and Neck Cancers

News provided by

Aspyrian Therapeutics Inc.

Jul 27, 2015, 03:59 ET